We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?
Read MoreHide Full Article
Key Takeaways
INSP shares rose 12.1% in three months despite a 7.9% revenue decline and a 62.2% drop in adjusted Q3 EPS.
Reimbursement issues reduced Inspire's Q3 revenues by $30M, with the full-year 2026 impact pegged at $120M.
Inspire targets low-single-digit revenue growth in 2027, backed by Project Horizon and battery replacements.
Inspire Medical Systems, Inc. (INSP - Free Report) shares have gained 12.1% in the past three months, even as reimbursement disruption has continued to weigh on procedure conversion and revenues.
The next leg of the rally depends on whether improving operating trends and a clearer path to 2027 growth can offset still-soft near-term fundamentals.
INSP's Three-Month Gain Meets a Mixed Fundamental Backdrop
Third-quarter 2026 revenues fell 7.9% year over year to $206.7 million, while adjusted earnings per share (EPS) dropped 62.2% to 14 cents. Both metrics still topped the Zacks Consensus Estimate, with revenues beating by 1.2% and earnings exceeding the consensus mark by 40%.
The quarter also showed sequential progress. Revenues rose 3% from the second quarter as U.S. implanting centers became more comfortable with the temporary coding framework, helping explain why the stock's recent momentum has strengthened despite year-over-year contraction.
Reimbursement Friction Still Caps Inspire's Conversion
Coding and reimbursement issues reduced third-quarter revenues by approximately $30 million and Inspire Medical expects the full-year 2026 impact to reach roughly $120 million. Surgeon reimbursement remains inconsistent, while the WISeR prior-authorization program in six Medicare pilot states continues to add administrative steps that can delay procedures.
The broader treatment landscape also keeps patient conversion competitive. ResMed Inc. (RMD - Free Report) remains a major provider of continuous positive airway pressure therapy, the frontline standard of care for obstructive sleep apnea. Nyxoah SA (NYXH - Free Report) , meanwhile, focuses on obstructive sleep apnea through its Genio system, a bilateral hypoglossal nerve stimulation therapy.
INSP's 2027 Recovery Case Depends on Patient Flow
Management expects low-single-digit worldwide revenue growth in 2027, supported by a more stable coding environment, growth investments and a larger contribution from battery replacement procedures. That outlook suggests recovery, but not a rapid return to the company's earlier growth profile.
Project Horizon is central to the plan. The program created approximately $30 million of annualized investment capacity, which Inspire is redirecting toward patient engagement, education, navigation and additional field resources in about 40 high-potential markets.
Inspire's Valuation Leaves Room but Not a Clear Bargain
INSP trades at 2.1X forward 12-month sales, below its five-year median of 6.5X and the Zacks sub-industry's 4.3X. The discount leaves room for multiple expansion if revenue growth stabilizes and reimbursement execution improves.
Still, valuation alone does not settle the case. The Zacks Consensus Estimate calls for 2026 revenues of $856 million, down from $912 million in 2025, while adjusted earnings are projected at $1.29 per share versus $2.42 in 2025.
Image Source: Zacks Investment Research
INSP's Momentum Signal Offsets Softer Growth Scores
The rally can continue if procedure conversion improves and the 2027 growth plan gains traction, but reimbursement execution remains the key swing factor. The current setup supports a balanced view rather than an aggressive chase after the recent gain.
INSP currently carries a Zacks Rank #3 (Hold) and a VGM Score of B. Its Momentum Score of A fits the recent share-price strength and a 3.4% four-week increase in the current-year earnings estimate, while the Value Score of C and Growth Score of C temper that signal. The combination suggests improving momentum, but not enough evidence yet for a clearly stronger investment stance.
View the Zacks #1 Rank List
Image: Shutterstock
INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?
Key Takeaways
Inspire Medical Systems, Inc. (INSP - Free Report) shares have gained 12.1% in the past three months, even as reimbursement disruption has continued to weigh on procedure conversion and revenues.
The next leg of the rally depends on whether improving operating trends and a clearer path to 2027 growth can offset still-soft near-term fundamentals.
INSP's Three-Month Gain Meets a Mixed Fundamental Backdrop
Third-quarter 2026 revenues fell 7.9% year over year to $206.7 million, while adjusted earnings per share (EPS) dropped 62.2% to 14 cents. Both metrics still topped the Zacks Consensus Estimate, with revenues beating by 1.2% and earnings exceeding the consensus mark by 40%.
The quarter also showed sequential progress. Revenues rose 3% from the second quarter as U.S. implanting centers became more comfortable with the temporary coding framework, helping explain why the stock's recent momentum has strengthened despite year-over-year contraction.
Inspire Medical Systems, Inc. Price and Consensus
Inspire Medical Systems, Inc. price-consensus-chart | Inspire Medical Systems, Inc. Quote
Reimbursement Friction Still Caps Inspire's Conversion
Coding and reimbursement issues reduced third-quarter revenues by approximately $30 million and Inspire Medical expects the full-year 2026 impact to reach roughly $120 million. Surgeon reimbursement remains inconsistent, while the WISeR prior-authorization program in six Medicare pilot states continues to add administrative steps that can delay procedures.
The broader treatment landscape also keeps patient conversion competitive. ResMed Inc. (RMD - Free Report) remains a major provider of continuous positive airway pressure therapy, the frontline standard of care for obstructive sleep apnea. Nyxoah SA (NYXH - Free Report) , meanwhile, focuses on obstructive sleep apnea through its Genio system, a bilateral hypoglossal nerve stimulation therapy.
INSP's 2027 Recovery Case Depends on Patient Flow
Management expects low-single-digit worldwide revenue growth in 2027, supported by a more stable coding environment, growth investments and a larger contribution from battery replacement procedures. That outlook suggests recovery, but not a rapid return to the company's earlier growth profile.
Project Horizon is central to the plan. The program created approximately $30 million of annualized investment capacity, which Inspire is redirecting toward patient engagement, education, navigation and additional field resources in about 40 high-potential markets.
Inspire's Valuation Leaves Room but Not a Clear Bargain
INSP trades at 2.1X forward 12-month sales, below its five-year median of 6.5X and the Zacks sub-industry's 4.3X. The discount leaves room for multiple expansion if revenue growth stabilizes and reimbursement execution improves.
Still, valuation alone does not settle the case. The Zacks Consensus Estimate calls for 2026 revenues of $856 million, down from $912 million in 2025, while adjusted earnings are projected at $1.29 per share versus $2.42 in 2025.
Image Source: Zacks Investment Research
INSP's Momentum Signal Offsets Softer Growth Scores
The rally can continue if procedure conversion improves and the 2027 growth plan gains traction, but reimbursement execution remains the key swing factor. The current setup supports a balanced view rather than an aggressive chase after the recent gain.
Year to date, shares of Inspire Medical declined 30.3% against the industry’s 23.1% growth. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Image Source: Zacks Investment Research
INSP currently carries a Zacks Rank #3 (Hold) and a VGM Score of B. Its Momentum Score of A fits the recent share-price strength and a 3.4% four-week increase in the current-year earnings estimate, while the Value Score of C and Growth Score of C temper that signal. The combination suggests improving momentum, but not enough evidence yet for a clearly stronger investment stance.